UHN Start-up Nanovista Inc. closes $2.3 million seed round to advance its multimodal visualization agent towards clinical trials
Toronto, Canada – Nanovista Inc. (“Nanovista”) develops multimodal visualization agents designed to improve the performance of image-guided high-precision cancer therapy. The seed round financing was led by GreenSky Capital Inc. and its affiliated venture funds, the GreenSky Accelerator Funds I and GreenSky Accelerator Funds II, who made a $750,000 lead investment as part of a $2.3M seed round investment.
Nanovista was founded by a world-renowned team of scientists within the University Health Network and the University of Toronto and supported by top clinical oncologists. Nanovista’s first product, comprised of a stable lipid-based nanotechnology, provides long lasting illumination of tumors during the surgical planning stage and inside the operating room with the potential to significantly improve outcomes of cancer surgeries. Along with her co-founders Drs. David Jaffray and Jinzi Zheng, Dr. Christine Allen, President of Nanovista, says that “the funds raised will be used to complete the final stage of pre-clinical studies and a Phase I clinical trial in head and neck and lung cancer surgical patients”.
Despite being at an early stage, Nanovista’s proprietary technology has been recognized by Scientific American, naming them “one of ten start-ups changing healthcare” (https://goo.gl/tQqRVh).
Steven Chackowicz, Nanovista’s CEO said: “We are thrilled to have closed this investment round with GreenSky and the management team greatly values GreenSky’s high engagement in filling this round. Having worked in the space for over 20 years, I am excited about Nanovista’s impressive scientific team and the direct and practical impact that Nanovista can have on visualizing tumor margins in real-time.”
Michael List, Principal at GreenSky Capital added: “The Nanovista team have developed a best-in-class technology; adding a CEO with Steven’s experience makes this a compelling investment and an exciting addition to our portfolio.”
Nanovista’s multimodal visualization agents are designed to improve the performance of image-guided cancer therapy as a critical tool within precision medicine. For further information, please visit www.nanovista.com.
About GreenSky Capital Inc.
GreenSky Capital Inc. is an award-winning Toronto-based firm that provides merchant bank and corporate financial advisory services to small and medium sized technology firms. GreenSky Capital makes investments in early-stage Canadian technology companies through its affiliated venture capital funds, GreenSky Accelerator Fund I, LP and GreenSky Accelerator Fund II, LP. GreenSky principals bring a unique combination of experience in technology, law and finance to high-growth potential companies and dedicated entrepreneurs. See www.greenskycapital.com.
Early-stage Canadian technology companies interested in working with Fund II are invited to learn more about, and apply to, the GreenSky Accelerator Funds at: email@example.com
or by visiting the website at: https://www.greenskycapital.com/entrepreneurs/#application.